William Blair Lowers CeriBell’s Earnings Estimates for Q1 2025

CeriBell (NASDAQ:CBLL – Free Report) recently saw a reduction in its Q1 2025 earnings estimates by William Blair’s research analysts. This adjustment was made in a report published on February 26th. Analyst M. Andrew now forecasts that CeriBell will report earnings per share of ($0.44) for the upcoming quarter, a decrease from a prior estimate of ($0.30).

Despite the lowered earnings estimate, William Blair maintains an "Outperform" rating on CeriBell's stock. The consensus projection for the company’s total earnings for the current fiscal year is set at ($2.46) per share. Moreover, William Blair has released additional earnings estimates for subsequent quarters, suggesting ($0.46) EPS for Q2 2025, ($0.45) EPS for Q3 2025, and ($0.45) EPS for Q4 2025. The overall earnings estimate for FY2025 stands at ($1.81) EPS, while Q1 2026 is projected at ($0.37) EPS, and Q2 and Q3 2026 are both anticipated at ($0.35) EPS, with Q4 2026 estimated at ($0.33) EPS. The FY2026 total is forecasted to be ($1.40) EPS.

Other market analysts have also shared their insights on CeriBell. Canaccord Genuity Group reaffirmed a "buy" rating with a price target of $33.00 in a recent report. Bank of America commenced coverage with a "buy" rating and set a price target of $32.00 on November 5th. Similarly, JPMorgan Chase & Co. initiated coverage on the same day with an "overweight" rating and a $32.00 price target. In December, TD Cowen increased their price target from $31.00 to $36.00, maintaining a "buy" rating. A summary of recent analyst reports shows six analysts currently recommend buying the stock, with an average target price of $32.60 based on MarketBeat.com data.

Current Stock Performance

On the last trading day, CeriBell's stock opened at $23.24, representing a 2.2% decrease. The stock has experienced a 12-month trading range, with a low of $18.69 and a high of $32.75. The 50-day moving average price stands at $23.34.

CeriBell's most recent earnings report was released on February 25th, indicating a loss of ($0.40) EPS for the quarter, which fell short of the consensus estimate of ($0.32) by $0.08. On the revenue side, the reported amount was $18.53 million, exceeding analysts' expectations of $17.55 million.

Institutional Investor Activity

In recent months, several institutional investors have adjusted their holdings in CeriBell. FMR LLC made a notable investment, acquiring shares valued at approximately $128,120,000 during the fourth quarter. Additionally, Corebridge Financial Inc. purchased shares valued at about $158,000, along with the Board of Trustees of The Leland Stanford Junior University acquiring $16,143,000 worth of shares. Other transactions include Norges Bank’s new position worth $422,000 and Next Century Growth Investors LLC acquiring approximately $5,299,000.

CeriBell Overview

As a commercial-stage medical technology company, CeriBell focuses on enhancing the diagnosis and management of patients suffering from serious neurological conditions. The company’s flagship product, the Ceribell System, is a pioneering point-of-care electroencephalography (EEG) platform tailored to meet the specific needs of patients in acute care settings.

CeriBell, Earnings, Estimates